author-photo

Raquel Izumi

79

Papers

3179

Citations

Citation Trend

Filter By

Papers (53) Sort By

Journal Conference Others

VIP152, a Selective CDK9 Inhibitor, Induces Complete Regression in a High-Grade B-Cell Lymphoma (HGBL) Model and Depletion of Short-Lived Oncogenic Driver Transcripts, MYC and MCL1, with a Once Weekly Schedule

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.

2021 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1314: A novel small molecule drug conjugate -avb3 integrin antagonist linked to a cytotoxic camptothecin derivative- for the treatment of multiple cancer types

2021
Show All
- Source
- Cite
- Save
Citations (0)
Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.

2021 Haematologica
Show All
- Source
- Cite
- Save
Citations (8)
Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL)

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Acalabrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

2021 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Pharmacodynamic analysis of BTK inhibition in patients with chronic lymphocytic leukemia treated with acalabrutinib

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (6)
Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

2020 Science immunology
Show All
- Source
- Cite
- Save
Citations (196)
Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)